Claims

[Claim 1]

Use of a composition comprising 1×10^{10} or more viable cells of Lactobacillus casei YIT9029 in the manufacture of a medicament for the treatment of Type 2 diabetes by improving early insulin secretory capacity, wherein the medicament is to be administered to a human subject having an early insulinogenic index of less than 0.4.

[Claim 2]

The use according to claim 1, wherein the medicament is configured such that 1×10^{10} or more viable cells of Lactobacillus casei YIT9029 are to be ingested per day.